ToxEM LLC is a pharmaceutical company based in Alexandria, VA, dedicated to developing drugs derived from botanical sources to target life-threatening illnesses with significant impact on public health. Led by a team with extensive experience in biopharmaceuticals, toxicology, botany, and emergency medicine, ToxEM aims to capitalize on the FDA's guidance for the development of new therapies from botanical sources. Their first drug product, TXM-24631, focuses on treating disseminated intravascular coagulopathy (DIC), a complex bleeding disorder associated with sepsis and other acute diseases, with the potential for future indications in thromboembolic diseases. With a founder and board member, Dr. Mary E. Palmer, who brings expertise in botany, emergency medicine, toxicology, and environmental conservation, ToxEM combines diverse fields to drive research and education. Dr. Palmer's background includes extensive work in endangered plant populations and evidence-based clinical standards, making her a valuable asset to the company. Additionally, Dr. Stephen N. Kirnon, a business advisor and board member, brings over 20 years of operational experience in biomedical organizations, further strengthening ToxEM's leadership team.
Generated from the website